Literature DB >> 3002214

Response of cattle persistently infected with noncytopathic bovine viral diarrhea virus to vaccination for bovine viral diarrhea and to subsequent challenge exposure with cytopathic bovine viral diarrhea virus.

S R Bolin, A W McClurkin, R C Cutlip, M F Coria.   

Abstract

Nine steers persistently infected with noncytopathic bovine viral diarrhea (BVD) virus were allotted into 3 groups (3 cattle/group). Cattle in group A were vaccinated with a modified-live BVD virus vaccine of porcine cell origin, cattle in group B with a modified-live BVD virus vaccine of bovine cell origin, and cattle in group C with a killed BVD virus vaccine of bovine cell origin. Detrimental effects due to vaccination were not seen. Six weeks after vaccination, the steers were challenge exposed with a cytopathic BVD virus. All steers developed mucosal disease after challenge exposure, produced antibodies that neutralized various isolates of BVD virus, and remained persistently infected until death. Steers given killed virus vaccine had a minimal neutralizing-antibody response and developed mucosal disease as quickly as reported for challenge-exposed, nonvaccinated, persistently infected cattle. Steers given modified-live virus vaccines had higher neutralizing-antibody response and longer intervals from challenge exposure to development of mucosal disease. The specificity of the neutralizing-antibody response differed between groups of vaccinated cattle.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3002214

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  14 in total

1.  Molecular cloning of complementary DNA from a pneumopathic strain of bovine viral diarrhea virus and its diagnostic application.

Authors:  K V Brock; D A Brian; B T Rouse; L N Potgieter
Journal:  Can J Vet Res       Date:  1988-10       Impact factor: 1.310

2.  BVD virus antigens in tissues of persistently viraemic, clinically normal cattle: implications for the pathogenesis of clinically fatal disease.

Authors:  H Bielefeldt Ohmann
Journal:  Acta Vet Scand       Date:  1988       Impact factor: 1.695

3.  Monoclonal antibodies with neutralizing activity segregate isolates of bovine viral diarrhea virus into groups. Brief report.

Authors:  S Bolin; V Moennig; N E Kelso Gourley; J Ridpath
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

4.  Neutralizing antibodies to type 1 and 2 bovine viral diarrhea viruses: detection by inhibition of viral cytopathology and infectivity by immunoperoxidase assay.

Authors:  R W Fulton; J T Saliki; L J Burge; J M d'Offay; S R Bolin; R K Maes; J C Baker; M L Frey
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

5.  Monoclonal antibodies to the p80/125 gp53 proteins of bovine viral diarrhea virus: their potential use as diagnostic reagents.

Authors:  D Deregt; S A Masri; H J Cho; H Bielefeldt Ohmann
Journal:  Can J Vet Res       Date:  1990-06       Impact factor: 1.310

6.  Severe thrombocytopenia in young calves experimentally infected with noncytopathic bovine viral diarrhea virus.

Authors:  W V Corapi; T W French; E J Dubovi
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

7.  Detection of BVD viruses using synthetic oligonucleotides.

Authors:  T L Lewis; J F Ridpath; S R Bolin; E S Berry
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

8.  Prevaccination bovine viral diarrhea virus titers and subsequent reproductive performance in dairy heifers.

Authors:  P Michel; M Thurmond; S Hietala
Journal:  Can J Vet Res       Date:  1993-10       Impact factor: 1.310

9.  Monoclonal antibody analyses of cytopathic and noncytopathic viruses from fatal bovine viral diarrhea virus infections.

Authors:  W V Corapi; R O Donis; E J Dubovi
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

10.  New concepts in the pathogenesis, diagnosis and control of diseases caused by the bovine viral diarrhea virus.

Authors:  O M Radostits; I R Littlejohns
Journal:  Can Vet J       Date:  1988-06       Impact factor: 1.008

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.